Video Shorts

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.

Learn about successful treatment of 72 year old Renal Cell Carcinoma Patient also suffering from Rheumatoid Arthritis treated with single agent TKI

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

Immunotherapy has redefined the treatment of Triple Negative Breast Cancer.